Overall, our study found that new type inhibitor MI-2 has certain improvement effect on DSS-induced murine colitis by targeting MALT1-NF-κB and NLRP3 signal pathway, which suggests a new strategy for clinical treatment of colitis. This evidence concerns the gene MALT1 and colitis.